Holen Sie sich die Stockscreener-App
94.20
3.09%
-3.00
Handel nachbörslich:
93.67
-0.53
-0.56%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$97.20
Offen:
$97.91
24-Stunden-Volumen:
3.75M
Relative Volume:
1.65
Marktkapitalisierung:
$14.92B
Einnahmen:
$4.39B
Nettoeinkommen (Verlust:
$-1.58B
KGV:
-9.4578
EPS:
-9.96
Netto-Cashflow:
$546.00M
1W Leistung:
-6.03%
1M Leistung:
-33.34%
6M Leistung:
-28.97%
1J Leistung:
-30.94%
1-Tages-Spanne:
$93.50
$98.70
1-Wochen-Bereich:
$93.50
$105.67
52-Wochen-Spanne:
$93.50
$156.66
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Vergleichen Sie ILMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
94.20 | 14.92B | 4.39B | -1.58B | 546.00M | -9.96 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Roche looks to grow with sequencing by expansion tech - BioWorld Online
Illumina stock touches 52-week low at $94.72 amid market challenges By Investing.com - Investing.com South Africa
Illumina stock touches 52-week low at $94.72 amid market challenges - Investing.com
Constellation technology saves valuable time and unlocks a more complete genome - Illumina
Illumina, Broad Clinical Labs Partner to Expedite Single-Cell Research -February 21, 2025 at 09:59 am EST - Marketscreener.com
Illumina and Broad Clinical Labs enhance single-cell research - Investing.com
Illumina And Broad Clinical Labs Usher In New Era Of Drug Discovery With Collaboration To Rapidly Scale Single-Cell Solutions - Marketscreener.com
Can 5 Billion Cells Revolutionize Drug Discovery? Illumina's Latest Breakthrough - StockTitan
Circulating Cell-Free Tumor DNA Market Witnessing Substantial - openPR
Ownership Capital B.V. Cuts Stock Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Baillie Gifford & Co. - MarketBeat
Short Interest in Illumina, Inc. (NASDAQ:ILMN) Expands By 9.0% - MarketBeat
China blacklists Illumina, triggers frenzy among rivals to win market share - Medical Buyer
Illumina: New Entrant Roche Aims to Launch Sequencing Platform in 2026 - Morningstar
Illumina's Large Installed System Base Should Insulate It Somewhat From New Entrants - Morningstar
Illumina teases transcriptome profiling tech ahead of 2026 launch - Yahoo Finance
10,958 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by Strategic Financial Concepts LLC - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Buys New Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Principal Financial Group Inc. - MarketBeat
Allworth Financial LP Increases Stock Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina unveils first-of-its-kind spatial transcriptomics technology - BSI bureau
Exome Sequencing Market Is Booming So Rapidly: Illumina, Inc. (USA), Thermo Fisher Scientific, Inc. (USA) - openPR
Chinese Rivals Seize on Illumina’s Blacklisting to Woo Clients - Bloomberg
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Rhumbline Advisers - MarketBeat
Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference - Eastern Progress
Cathie Wood Explains AI Growth Catalysts for Illumina (ILMN) - Insider Monkey
Why Illumina Inc. (ILMN) Went Down on Monday - MSN
TD Cowen holds Illumina stock with $140 target By Investing.com - Investing.com UK
Illumina Unveils Spatial Technology Days Before AGBT Meeting - Genetic Engineering & Biotechnology News
Illumina (NASDAQ:ILMN) Reaches New 1-Year LowHere's What Happened - MarketBeat
The Dawn of Genetic Mastery? Meet Illumina’s New Frontier. - Jomfruland.net
BofA Securities Cuts Price Target on Illumina to $90 From $110, Keeps Underperform Rating - Marketscreener.com
Biomarker Research Services Market Set to Witness Significant Growth by 2025-2032:Siemens Healthineers AG, - EIN News
Van ECK Associates Corp Purchases 22,718 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
DNA Test Kits Market Future Business Opportunities 2025-2032 | - openPR
Microfluidic Market Growth in Future Scope 2025-2032 | Agilent Technologies, Inc., Illumina, Inc., Perkinelmer, Inc. - openPR
Chevy Chase Trust Holdings LLC Boosts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Illumina's SWOT analysis: stock outlook amid sequencing market shifts - MSN
Illumina’s SWOT analysis: stock outlook amid sequencing market shifts By Investing.com - Investing.com Nigeria
Single Cell Genome Sequencing Market to Witness Rapid Expansion - openPR
Life Science Tools Market Is Booming Worldwide 2025-2032: Hitachi, Ltd., Illumina, Inc., Oxford Instruments, - EIN News
New York State Teachers Retirement System Sells 2,900 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Asset Management One Co. Ltd. Increases Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina Inc.: Is its Transition to NovaSeq X Series Noteworthy? - Smartkarma
Brokerages Set Illumina, Inc. (NASDAQ:ILMN) Price Target at $159.45 - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Makes New $448,000 Investment in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina partners with Nvidia on AI-powered genomic sequencing - MSN
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Louisiana State Employees Retirement System - MarketBeat
Banque Pictet & Cie SA Trims Stake in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina (NASDAQ:ILMN) Stock Rating Lowered by Barclays - MarketBeat
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
3.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):